New combo tackles tough melanoma
NCT ID NCT06540391
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 24 times
Summary
This early-stage trial tests whether adding an experimental treatment (MB097) to a standard immunotherapy (pembrolizumab) is safe and shows signs of working in people with advanced melanoma that did not respond to prior anti-PD1 therapy. About 41 participants will receive the combination. The main goal is to check for side effects and see if tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hopital de la Timone
Marseille, France
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
-
CHU de Lille - Hopital Claude Huriez
Lille, France
-
Centre Georges Francois Leclerc
Dijon, France
-
Centre Leon Berard
Lyon, France
-
Consorcio Hospital General Universitario de Valencia
Valencia, Spain
-
Freeman Hospital
Newcastle, United Kingdom
-
HCL Centre Hospitalier Lyon Sud
Pierre-Bénite, France
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Spain
-
Istituto Clinico Humanitas
Rozzano, Italy
-
Istituto Europeo di Oncologia
Milan, Italy
-
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, Italy
-
Royal Marsden Hospital - Surrey
Sutton, United Kingdom
-
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, Spain
-
Sussex Cancer Centre
Brighton, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, United Kingdom
Conditions
Explore the condition pages connected to this study.